Drug intelligence / Profile preview

epinephrine + propranolol

Development stage
Discontinued
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Subcutaneous, Inhalation
01

Overview

Epinephrine + propranolol is a combination of two pharmacologically active agents with opposing actions on the adrenergic system. Epinephrine (adrenaline) is a hormone and neurotransmitter that acts as an agonist at both alpha- and beta-adrenergic receptors, leading to increased heart rate, vasoconstriction, bronchodilation, and other sympathetic effects. It is used in emergency medicine for anaphylaxis, cardiac arrest, asthma exacerbations, and as a vasoconstrictor adjunct in local anesthesia[4]. Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) that reduces heart rate and myocardial contractility by blocking the effects of endogenous catecholamines like epinephrine and norepinephrine[6][8][10]. It is indicated for hypertension, angina pectoris, arrhythmias, migraine prophylaxis, essential tremor, anxiety disorders, among others[5][6][8][10]. When combined—intentionally or unintentionally—propranolol blocks the beta-mediated effects of epinephrine while leaving alpha-mediated vasoconstriction unopposed. This can result in severe hypertension and bradycardia due to unopposed alpha-adrenergic stimulation by epinephrine[7][9]. The combination does not have recognized therapeutic use due to this dangerous interaction; it is generally contraindicated except under special circumstances.

02

Targets

ADRB3 (β3)ADRA2 (Adrenergic alpha-2 receptor family)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)

Beyond the preview

Go deeper on epinephrine + propranolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epinephrine + propranolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call